Current Environment: Production

Warning

Recall Alert

There is an antibacterial antibiotic recall. Read more

What is ornithine transcarbamylase (OTC) deficiency?

OTC deficiency is caused by mutations in the gene encoding the ornithine transcarbamylase (OTC) enzyme. This enzyme is responsible for detoxification of the ammonia that forms when proteins are broken down in the body. When there is not enough OT, ammonia builds up in the bloodstream. This can become toxic at high levels, potentially causing neurological impairments and eventual liver damage.

The most common form of OTC deficiency, occurring in both males and females, is a late-onset form. Although late-onset OTC deficiency is considered milder than neonatal-onset OTC deficiency, which affects newborns, it is still considered a serious condition. Currently, the only curative treatment is liver transplantation.

Ornithine Transcarbamylase Deficiency | Diagnosis & Treatments

Gene therapy for OTC deficiency

Boston Children’s recently participated in a gene therapy trial for patients with late-onset OTC. The therapy used an adenovirus vector to deliver a healthy copy of the OTC gene through an IV infusion. For more information, contact gene.therapy@childrens.harvard.edu.

Ornithine Transcarbamylase Deficiency | Programs & Services

Talk to Lesley

If this is a medical emergency, please dial 9-1-1. This application should not be used in an emergency. This chat is being transmitted via a secure connection.

Hi! My name is Lesley. I am a virtual agent programmed to help you. If you would like to speak to a live agent, please call 617-355-6000.

For questions regarding an appointment, doctor notes, or specific questions related to symptoms/diagnosis, please call the department of clinic directly.

Quick links:

- MyChildrens Portal
- Global Services
- Find a Doctor
- Find a Location
- Programs and Services